These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 25185097)

  • 61. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.
    Thigpen JT; Brady MF; Homesley HD; Malfetano J; DuBeshter B; Burger RA; Liao S
    J Clin Oncol; 2004 Oct; 22(19):3902-8. PubMed ID: 15459211
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
    Gounder M; Schöffski P; Jones RL; Agulnik M; Cote GM; Villalobos VM; Attia S; Chugh R; Chen TW; Jahan T; Loggers ET; Gupta A; Italiano A; Demetri GD; Ratan R; Davis LE; Mir O; Dileo P; Van Tine BA; Pressey JG; Lingaraj T; Rajarethinam A; Sierra L; Agarwal S; Stacchiotti S
    Lancet Oncol; 2020 Nov; 21(11):1423-1432. PubMed ID: 33035459
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
    Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
    Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas.
    De Pas T; Curigliano G; Masci G; Catania C; Comandone A; Boni C; Tucci A; Pagani O; Marrocco E; de Braud F;
    Ann Oncol; 2002 Jan; 13(1):161-6. PubMed ID: 11863099
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.
    Badar T; Handisides DR; Benito JM; Richie MA; Borthakur G; Jabbour E; Harutyunyan K; Konoplev S; Faderl S; Kroll S; Andreeff M; Pearce T; Kantarjian HM; Cortes JE; Thomas DA; Konopleva M
    Am J Hematol; 2016 Aug; 91(8):800-5. PubMed ID: 27169385
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation.
    Gupta S; Gouw L; Wright J; Chawla S; Pitt D; Wade M; Boucher K; Sharma S
    Invest New Drugs; 2016 Apr; 34(2):243-52. PubMed ID: 26897615
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group.
    Steward WP; Verweij J; Somers R; Blackledge G; Clavel M; Van Oosterom AT; Greifenberg B; Soedirman J; Thomas D; Van Glabbeke M
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S193-7. PubMed ID: 1795008
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys.
    Jung D; Lin L; Jiao H; Cai X; Duan JX; Matteucci M
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):643-54. PubMed ID: 21964906
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin.
    Jones B; Komarnitsky P; Miller GT; Amedio J; Wallner BP
    Anticancer Drugs; 2012 Feb; 23(2):173-84. PubMed ID: 22027537
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

  • 71. First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.
    Schöffski P; Delord JP; Brain E; Robert J; Dumez H; Gasmi J; Trouet A
    Eur J Cancer; 2017 Nov; 86():240-247. PubMed ID: 29055839
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials.
    Younger E; Litière S; Le Cesne A; Mir O; Gelderblom H; Italiano A; Marreaud S; Jones RL; Gronchi A; van der Graaf WTA
    Oncologist; 2018 Oct; 23(10):1250-1259. PubMed ID: 29650688
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.
    Sun JD; Liu Q; Ahluwalia D; Ferraro DJ; Wang Y; Jung D; Matteucci MD; Hart CP
    Cancer Biol Ther; 2016 Apr; 17(4):371-80. PubMed ID: 26818215
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study.
    Zalupski M; Metch B; Balcerzak S; Fletcher WS; Chapman R; Bonnet JD; Weiss GR; Ryan J; Benjamin RS; Baker LH
    J Natl Cancer Inst; 1991 Jul; 83(13):926-32. PubMed ID: 2067035
    [TBL] [Abstract][Full Text] [Related]  

  • 75. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
    Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
    Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
    [TBL] [Abstract][Full Text] [Related]  

  • 76. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials.
    Young RJ; Natukunda A; Litière S; Woll PJ; Wardelmann E; van der Graaf WT
    Eur J Cancer; 2014 Dec; 50(18):3178-86. PubMed ID: 25459395
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.
    Oh SY; Kim WS; Kim JS; Kim SJ; Yoon DH; Yang DH; Lee WS; Kim HJ; Yhim HY; Jeong SH; Won JH; Lee S; Kong JH; Lim SN; Ji JH; Kwon KA; Lee GW; Lee JH; Lee HS; Shin HJ; Suh C
    Cancer Commun (Lond); 2019 Oct; 39(1):58. PubMed ID: 31619290
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination.
    De Pas T; Rosati G; Spitaleri G; Boni C; Tucci A; Frustaci S; Scalamogna R; Radice D; Boselli S; Toffalorio F; Catania C; Noberasco C; Delmonte A; Vecchio F; de Braud F
    Chemotherapy; 2011; 57(3):217-24. PubMed ID: 21597285
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
    Edmonson JH; Petersen IA; Shives TC; Mahoney MR; Rock MG; Haddock MG; Sim FH; Maples WJ; O'Connor MI; Gunderson LL; Foo ML; Pritchard DJ; Buckner JC; Stafford SL
    Cancer; 2002 Feb; 94(3):786-92. PubMed ID: 11857314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.